Drug Profile
Granisetron intranasal - Yunfeng Pharmaceutical
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Institute of Pharmacology and Toxicology Academy of Military Medical Sciences PLA
- Developer Yunfeng Pharmaceutical
- Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chemotherapy-induced nausea and vomiting
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Chemotherapy-induced-nausea-and-vomiting in China (Intranasal, Spray)
- 25 Nov 2015 Clinical trials in Chemotherapy induced nausea and vomiting in China (Intranasal)